Colin Walsh is Chief Executive and founder of Crescent Capital and has been an active venture capital investor in the high-tech sector for the past twenty eight years. He has considerable experience of business strategy and governance issues, mentoring senior management plus the restructuring, growth and development of companies across many sectors. He has served on numerous boards including both as a director and chair of Andor Technology plc, an AIM listed company and Trafficmaster plc, a LSE main market listed company. A former chair of the CBI for Northern Ireland, he joined the Fusion Antibodies as a Director in 2007 as a representative of Crescent Capital. Colin is a member of the Company’s remuneration committee and Chair of the audit committee.